<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Iressa II-34- EN PI - clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:red;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:-.05pt;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.A-Heading1, li.A-Heading1, div.A-Heading1
	{mso-style-name:"A-Heading 1";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	font-family:"Verdana",sans-serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	font-family:"Tahoma",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	font-family:"Times New Roman",serif;}
p.A-TableText, li.A-TableText, div.A-TableText
	{mso-style-name:"A-Table Text";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.A-TableHeader, li.A-TableHeader, div.A-TableHeader
	{mso-style-name:"A-Table Header";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.A-TableFootnoteText, li.A-TableFootnoteText, div.A-TableFootnoteText
	{mso-style-name:"A-Table Footnote Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.3in;
	text-indent:-.3in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.A-TableTitle, li.A-TableTitle, div.A-TableTitle
	{mso-style-name:"A-Table Title";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	text-indent:-1.25in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.DocsubtitleAgency, li.DocsubtitleAgency, div.DocsubtitleAgency
	{mso-style-name:"Doc subtitle \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:32.0pt;
	margin-left:0in;
	line-height:18.0pt;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
p.RefAgency, li.RefAgency, div.RefAgency
	{mso-style-name:"Ref\. \(Agency\)";
	margin:0in;
	font-size:8.5pt;
	font-family:"Verdana",sans-serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.smalltext
	{mso-style-name:smalltext;
	font-family:"Times New Roman",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;
	color:red;
	text-decoration:underline;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 11.0in;
	margin:85.05pt 1.0in 1.0in 85.05pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 11.0in;
	margin:85.05pt 1.0in 1.0in 85.05pt;}
div.WordSection2
	{page:WordSection2;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>ANNEX I</b></p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=A-Heading1><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:green'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IRESSA
250&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each tablet contains 250&nbsp;mg of
gefitinib</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipients with known effect</span></u><span
lang=EN-GB>: </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each tablet contains 163.5&nbsp;mg of
lactose (as monohydrate).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each tablet contains 3.86 mg of sodium.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Film&#8209;coated tablets (tablet).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Tablets are brown, round, biconvex,
impressed with &#8220;IRESSA 250&#8221; on one side and plain on the other.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IRESSA is indicated as monotherapy for the
treatment of adult patients with locally advanced or metastatic non&#8209;small
cell lung cancer (NSCLC) with activating mutations of EGFR&#8209;TK (see
section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with IRESSA
should be initiated and supervised by a physician experienced in the use of
anti-cancer therapies.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
posology of IRESSA is one 250&nbsp;mg tablet once a day. If a dose is missed,
it should be taken as soon as the patient remembers. If it is less than
12&nbsp;hours to the next dose, the patient should not take the missed dose.
Patients should not take a double dose (two doses at the same time) to make up
for a forgotten dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of IRESSA in children and adolescents aged
less than 18&nbsp;years has not been established. There is no relevant use of
gefitinib in the paediatric population in the indication of NSCLC.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients with moderate to severe hepatic
impairment (Child-Pugh B or C) due to cirrhosis have increased plasma
concentrations of gefitinib. These patients should be closely monitored for
adverse events. Plasma concentrations were not increased in patients with
elevated aspartate transaminase (AST), alkaline phosphatase or bilirubin due to
liver metastases (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>No dose
adjustment is required in patients with impaired renal function at creatinine
clearance &gt;&nbsp;20&nbsp;ml/min. Only limited data are available in patients
with creatinine clearance </span><span lang=EN-GB style='font-family:Symbol'>&pound;</span><span
lang=EN-GB>&nbsp;20&nbsp;ml/min and caution is advised in these patients (see
section&nbsp;5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Elderly </span></i></p>

<p class=MsoNormal><span lang=EN-GB>No dose adjustment is required on the basis
of patient age (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>CYP2D6 poor metabolisers</span></i></p>

<p class=MsoNormal><span lang=EN-GB>No specific dose adjustment is recommended
in patients with known CYP2D6 poor metaboliser genotype, but these patients
should be closely monitored for adverse events (see section&nbsp;5.2).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>Dose adjustment due to toxicity</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients with poorly tolerated diarrhoea or
skin adverse reactions may be successfully managed by providing a brief (up to
14&nbsp;days) therapy interruption followed by reinstatement of the 250&nbsp;mg
dose (see section&nbsp;4.8). For patients unable to tolerate treatment after a
therapy interruption, </span><span lang=EN-GB>gefitinib should be discontinued
and an alternative treatment should be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The tablet may
be taken orally with or without food, at about the same time each day. The
tablet can be swallowed whole with some water or </span><span lang=EN-GB>if
dosing of whole tablets is not possible, tablets may be administered as a
dispersion in water (non&#8209;carbonated). No other liquids should be used. </span><span
lang=EN-GB>Without crushing it, the tablet should be dropped in half a glass of
drinking water. </span><span lang=EN-GB>The glass should be swirled
occasionally, until the tablet is dispersed (this may take up to
20&nbsp;minutes). The dispersion should be drunk immediately after dispersion
is complete (i.e. </span><span lang=EN-GB>within 60&nbsp;minutes). The glass
should be rinsed with half a glass of water, which should also be drunk. The
dispersion can also be administered through a naso&#8209;gastric </span><span
lang=EN-GB>or gastrostomy </span><span lang=EN-GB>tube.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substance or to any of the excipients </span><span lang=EN-GB>listed
in </span><span lang=EN-GB>section&nbsp;6</span><span lang=EN-GB>.1</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Breast&#8209;feeding
(see section&nbsp;4.6).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>When considering the use of IRESSA as a
treatment for locally advanced or metastatic NSCLC, it is important that EGFR
mutation assessment of the tumour tissue is attempted for all patients. </span><span
lang=EN-GB>If a tumour sample is not evaluable, then circulating tumour DNA
(ctDNA) obtained from a blood (plasma) sample may be used.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Only robust, reliable and sensitive test(s)
with demonstrated<i> </i>utility for the determination of EGFR mutation status
of tumours or ctDNA should be used to avoid false negative or false positive
determinations (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Interstitial
lung disease (ILD)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interstitial
lung disease (ILD) which may be acute in onset, has been observed in 1.3% of
patients receiving </span><span lang=EN-GB>gefitinib, and some cases have been
fatal (see section&nbsp;4.8). If patients experience worsening of respiratory
symptoms such as dyspnoea, cough and fever, IRESSA should be interrupted and
the patient should be promptly investigated. If ILD is confirmed, IRESSA should
be discontinued and the patient treated appropriately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a Japanese
pharmacoepidemiological case control study in 3,159&nbsp;patients with NSCLC
receiving </span><span lang=EN-GB>gefitinib or chemotherapy who were followed
up for 12&nbsp;weeks, the following risk factors for developing ILD
(irrespective of whether the patient received IRESSA or chemotherapy) were
identified: smoking, poor performance status (PS &#8805;&nbsp;2), CT scan
evidence of reduced normal lung (&#8804;&nbsp;50%), recent diagnosis of NSCLC
(&lt;&nbsp;6&nbsp;months), pre&#8209;existing ILD, older age
(&#8805;&nbsp;55&nbsp;years old) and concurrent cardiac disease. An increased
risk of ILD on gefitinib relative to chemotherapy was seen predominantly during
the first 4&nbsp;weeks of treatment (adjusted OR 3.8; 95% CI 1.9 to 7.7);
thereafter the relative risk was lower (adjusted OR 2.5; 95% CI 1.1 to 5.8).<span
style='color:black'> </span>Risk of mortality among patients who developed ILD
on IRESSA or chemotherapy was higher in patients with the following risk
factors: smoking, CT scan evidence of reduced normal lung (&#8804;&nbsp;50%),
pre&#8209;existing ILD, older age (&#8805;&nbsp;65&nbsp;years old), and extensive
areas adherent to pleura (&#8805;&nbsp;50%).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Hepatotoxicity and liver impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Liver function test abnormalities
(including <strong><span style='font-weight:normal'>increases in</span></strong></span><span
lang=EN-GB style='font-size:10.0pt'> </span><span lang=EN-GB>alanine
aminotransferase, aspartate aminotransferase, bilirubin) have been observed,
uncommonly presenting as hepatitis (see section&nbsp;4.8). There have been
isolated reports of hepatic failure which in some cases led to fatal outcomes.
Therefore, periodic liver function testing is recommended. Gefitinib should be
used cautiously in the presence of mild to moderate changes in liver function.
Discontinuation should be considered if changes are severe.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Impaired liver
function due to cirrhosis has been shown to lead to increased plasma
concentrations of gefitinib (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Interactions
with other medicinal products</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>CYP3A4&nbsp;inducers
may increase metabolism of gefitinib and decrease gefitinib plasma
concentrations. Therefore, concomitant administration of CYP3A4 inducers (e.g.
phenytoin, carbamazepine, rifampicin, barbiturates or herbal preparations
containing St John&#8217;s wort/<i>Hypericum perforatum</i>) may reduce
efficacy of the treatment and should be avoided (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In individual
patients with CYP2D6 poor metaboliser genotype, treatment with a potent CYP3A4
inhibitor might lead to increased plasma levels of gefitinib. At initiation of
treatment with a CYP3A4 inhibitor, patients should be closely monitored for
gefitinib adverse reactions (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>International
normalised ratio (INR) elevations and/or bleeding events have been reported in
some patients taking warfarin together with gefitinib (see section&nbsp;4.5).
Patients taking warfarin and gefitinib concomitantly should be monitored
regularly for changes in prothrombin time (PT) or INR.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
products that cause significant sustained elevation in gastric pH, such as
proton&#8209;pump inhibitors and h<sub>2</sub>&#8209;antagonists may reduce
bioavailability and plasma concentrations of gefitinib and, therefore, may
reduce efficacy. Antacids if taken regularly close in time to administration of
</span><span lang=EN-GB>gefitinib may have a similar effect (see
sections&nbsp;4.5 and 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Data from phase
II clinical trials, where gefitinib and vinorelbine have been used
concomitantly, indicate that gefitinib may exacerbate the neutropenic effect of
vinorelbine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Lactose</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IRESSA contains
lactose. Patients with rare hereditary problems of galactose intolerance, total
lactase deficiency or glucose&#8209;galactose malabsorption should not take
this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Sodium</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IRESSA contains
less than 1 mmol (23 mg) of sodium per tablet, that is to say it is essentially
&#8216;sodium-free.&#8217;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Further
precautions for use</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be advised to seek medical
advice immediately if they experience severe or persistent diarrhoea, nausea,
vomiting or anorexia as these may indirectly lead to dehydration. These
symptoms should be managed as clinically indicated (see section&nbsp;4.8).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Patients presenting
with signs and symptoms suggestive of keratitis such as acute or worsening: eye
inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or
red eye should be referred promptly to an ophthalmology specialist.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>If a diagnosis of ulcerative keratitis is confirmed,
treatment with </span><span lang=EN-GB>gefitinib<span style='color:black'>
should be interrupted, and if symptoms do not resolve, or if symptoms recur on
reintroduction of </span>gefitinib<span style='color:black'>, permanent
discontinuation should be considered.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a phase I/II
trial studying the use of gefitinib and radiation in paediatric patients, with
newly diagnosed brain stem glioma or incompletely resected supratentorial
malignant glioma, 4&nbsp;cases (1&nbsp;fatal) of Central Nervous System (CNS)
haemorrhages were reported from 45&nbsp;patients enrolled. A further case of
CNS haemorrhage has been reported in a child with an ependymoma from a trial
with gefitinib alone. An increased risk of cerebral haemorrhage in adult
patients with NSCLC receiving gefitinib has not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gastrointestinal
perforation has been reported in patients taking gefitinib. In most cases this
is associated with other known risk factors, including concomitant medications
such as steroids or NSAIDS, underlying history of GI ulceration, age, smoking
or bowel metastases at sites of perforation.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other medicinal
products and other forms of interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The metabolism
of gefitinib is via the cytochrome P450 isoenzyme CYP3A4 (predominantly) and
via CYP2D6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Active
substances that may increase gefitinib plasma concentrations</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies have shown that gefitinib is a substrate of p&#8209;glycoprotein
(Pgp). Available data do not suggest any clinical consequences to this <i>in
vitro</i> finding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Substances that
inhibit CYP3A4 may decrease the clearance of gefitinib. Concomitant
administration with potent inhibitors of CYP3A4 activity (e.g. ketoconazole,
posaconazole, voriconazole, protease inhibitors, clarithromycin, telithromycin)
may increase gefitinib plasma concentrations. The increase may be clinically
relevant since adverse reactions are related to dose and exposure. The increase
might be higher in individual patients with CYP2D6 poor metaboliser genotype.
Pre&#8209;treatment with itraconazole (a potent CYP3A4 inhibitor) resulted in
an 80% increase in the mean AUC of gefitinib in healthy volunteers. In
situations of concomitant treatment with potent inhibitors of CYP3A4 the
patient should be closely monitored for gefitinib adverse reactions.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>There are no data on concomitant treatment
with an inhibitor of CYP2D6 but potent inhibitors of this enzyme might cause
increased plasma concentrations of gefitinib in CYP2D6 extensive metabolisers
by about 2&#8209;fold (see section&nbsp;5.2). If concomitant treatment with a
potent CYP2D6 inhibitor is initiated, the patient should be closely monitored
for adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB>Active
substances that may reduce gefitinib plasma concentrations</span></i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='color:black'>Substances that are inducers of CYP3A4 activity may
increase metabolism and decrease gefitinib plasma concentrations and thereby
reduce the efficacy of </span><span lang=EN-GB>gefitinib<span style='color:
black'>. Concomitant medicinal products that induce CYP3A4 (e.g. phenytoin,
carbamazepine, rifampicin, barbiturates or St John&#8217;s wort/ <i>Hypericum
perforatum</i>) should be avoided. Pre&#8209;treatment with rifampicin (a potent
CYP3A4 inducer) in healthy volunteers reduced mean gefitinib AUC by 83% (see
section&nbsp;4.4).</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Substances that cause significant sustained
elevation in gastric pH may reduce gefitinib plasma concentrations and thereby
reduce the efficacy of gefitinib. High doses of short&#8209;acting antacids may
have a similar effect if taken regularly close in time to administration of
gefitinib. Concomitant administration of gefitinib with ranitidine at a dose
that caused sustained elevations in gastric pH &#8805;&nbsp;5 resulted in a
reduced mean gefitinib AUC by 47% in healthy volunteers (see section&nbsp;4.4
and 5.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Active substances that may have their
plasma concentrations altered by gefitinib</span></i></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
studies have shown that gefitinib has limited potential to inhibit CYP2D6. In a
clinical trial in patients, gefitinib was co&#8209;administered with metoprolol
(a CYP2D6 substrate). This resulted in a 35% increase in exposure to
metoprolol. Such an increase might potentially be relevant for CYP2D6
substrates with narrow therapeutic index. When the use of CYP2D6 substrates are
considered in combination with gefitinib, a dose modification of the CYP2D6
substrate should be considered especially for products with a narrow
therapeutic window.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gefitinib
inhibits the transporter protein BCRP <i>in vitro</i>, but the clinical
relevance of this finding is unknown.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Other
potential interactions</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>INR elevations
and/or bleeding events have been reported in some patients concomitantly taking
warfarin (see section&nbsp;4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span lang=EN-GB>Fertility,
p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Women of childbearing potential</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Women of
childbearing potential must be advised not to get pregnant during therapy.</span></p>

<p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data from the use of gefitinib in pregnant women. Studies in animals have shown
reproductive toxicity (see section&nbsp;5.3). The potential risk for humans is
unknown. IRESSA should not be used during pregnancy unless clearly necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is not known
whether gefitinib is secreted in human milk. Gefitinib and metabolites of
gefitinib accumulated in milk of lactating rats (see section&nbsp;5.3). </span><span
lang=EN-GB>Gefitinib is contraindicated during breast&#8209;feeding and
therefore breast&#8209;feeding must be discontinued while receiving gefitinib
therapy (see section&nbsp;4.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>During treatment
with gefitinib, asthenia has been reported. Therefore, patients who experience
this symptom should be cautious when driving or using machines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><u>Summary of the safety profile</u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the pooled
dataset from the </span><span lang=EN-GB>ISEL, INTEREST and IPASS phase III
clinical trials (2462&nbsp;IRESSA&#8209;treated patients)</span><span
lang=EN-GB>,</span><span lang=EN-GB> </span><span lang=EN-GB>the most
frequently reported adverse drug reactions (ADRs), occurring in more than 20%
of the patients, are diarrhoea and skin reactions (including rash, acne, dry
skin and pruritus). ADRs usually occur within the first month of therapy and
are generally reversible. Approximately 8% of patients had a severe ADR (common
toxicity criteria (CTC) grade 3 or 4). Approximately 3% of patients stopped
therapy due to an ADR.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Interstitial lung disease (ILD) has
occurred in 1.3% of patients, often severe (CTC grade 3&#8209;4). Cases with
fatal outcomes have been reported.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u>Tabulated list of adverse reactions</u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The safety profile presented in
Table&nbsp;1 is based on the gefitinib clinical development programme and
postmarketed experience. Adverse reactions have been assigned to the frequency
categories in Table&nbsp;1 </span><span lang=EN-GB>where possible </span><span
lang=EN-GB>based on the incidence of comparable adverse event reports in a
pooled dataset from the</span><span lang=EN-GB> ISEL, INTEREST and IPASS phase
III clinical trials (2462&nbsp;IRESSA&#8209;treated patients)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Frequencies of occurrence of undesirable
effects are defined as: very common (&#8805;&nbsp;1/10); common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100); rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare
(&lt;&nbsp;1/10,000), </span><span lang=EN-GB>not known (cannot be estimated
from the available data).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Within each frequency grouping, undesirable
effects are presented in order of decreasing seriousness.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 1 Adverse reactions</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Adverse reactions by system organ
  class and frequency</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Anorexia mild or moderate (CTC grade 1 or
  2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=2 valign=top style='width:154.45pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common </span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Conjunctivitis, blepharitis, and dry
  eye*, mainly mild (CTC grade 1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon </span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Corneal erosion, reversible and sometimes
  in association with aberrant eyelash growth</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Keratitis (0.12%)</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common </span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Haemorrhage, such as epistaxis and
  haematuria</span></p>
  </td>
 </tr>
 <tr>
  <td width=206 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Respiratory, thoracic and mediastinal
  disorders</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common </span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Interstitial lung disease (1.3%), often
  severe (CTC grade 3&#8209;4). Cases with fatal outcomes have been reported </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=8 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width=206 rowspan=4 valign=top style='width:154.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='color:black'>Diarrhoea, mainly
  mild or moderate (CTC grade 1 or 2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Vomiting, mainly mild or moderate (CTC
  grade 1 or 2)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nausea, mainly mild (CTC grade 1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Stomatitis, predominantly mild in nature
  (CTC grade 1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=2 valign=top style='width:154.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dehydration, secondary to diarrhoea,
  nausea, vomiting or anorexia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Dry mouth*, predominantly mild (CTC grade
  1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.4pt'>
  <td width=206 rowspan=2 valign=top style='width:154.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pancreatitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Gastrointestinal perforation</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=4 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hepatobiliary disorders</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Elevations in alanine aminotransferase,
  mainly mild to moderate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=2 valign=top style='width:154.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Elevations in aspartate aminotransferase,
  mainly mild to moderate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Elevations in total bilirubin, mainly
  mild to moderate</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Hepatitis**</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=6 valign=top style='width:154.45pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Skin reactions, mainly a mild or moderate
  (CTC grade 1 or 2) pustular rash, sometimes itchy with dry skin, including
  skin fissures, on an erythematous base</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=3 valign=top style='width:154.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Nail disorder</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Alopecia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Allergic reactions (1.1%), including</p>
  <p class=MsoNormal>angioedema and urticaria</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal>Palmar-plantar erythrodysaesthesia syndrome</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.5pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Bullous conditions including toxic
  epidermal necrolysis, Stevens Johnson syndrome and erythema multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cutaneous vasculitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=3 valign=top style='width:154.45pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Renal and urinary disorders</span></p>
  </td>
  <td width=206 rowspan=3 valign=top style='width:154.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Asymptomatic laboratory elevations in
  blood creatinine</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Proteinuria</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Cystitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Haemorrhagic cystitis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 rowspan=2 valign=top style='width:154.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>General disorders and administration site
  conditions</span></p>
  </td>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Asthenia, predominantly mild (CTC grade
  1)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=207 valign=top style='width:155.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Pyrexia</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>The frequency of
adverse drug reactions relating to abnormal laboratory values is based on
patients with a change from baseline of 2 or more CTC grades in the relevant
laboratory parameters.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*This adverse
reaction can occur in association with other dry conditions (mainly skin
reactions) seen with gefitinib.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>**</span><span
lang=EN-GB style='font-size:10.0pt'>This includes isolated reports of hepatic
failure which in some cases led to fatal outcomes.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Interstitial
lung disease (ILD)</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>In the INTEREST
trial, the incidence of ILD type events was 1.4% (10) patients in the gefitinib
group<i> versus</i> 1.1% (8) patients in the docetaxel group. </span><span
lang=EN-GB style='color:black'>One ILD&#8209;type event was fatal, and this
occurred in a patient receiving gefitinib.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the ISEL
trial, the incidence of ILD&#8209;type events in the overall population was
approximately 1% in both treatment arms. The majority of ILD&#8209;type events
reported was from patients of Asian ethnicity and the ILD incidence among
patients of Asian ethnicity receiving gefitinib therapy and placebo was
approximately 3% and 4% respectively. One ILD&#8209;type event was fatal, and
this occurred in a patient receiving placebo.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a post&#8209;marketing
surveillance study in Japan (3350&nbsp;patients) the reported rate of ILD&#8209;type
events in patients receiving gefitinib was 5.8%.</span><span lang=EN-GB
style='color:black'> The proportion of ILD&#8209;type events with a fatal
outcome was 38.6%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a phase III open&#8209;label clinical
trial (IPASS) in 1217&nbsp;patients comparing IRESSA to carboplatin/paclitaxel
doublet chemotherapy as first&#8209;line treatment in selected patients with
advanced NSCLC in Asia, the incidence of ILD&#8209;type events was 2.6% on the IRESSA
treatment arm versus 1.4% on the carboplatin/paclitaxel treatment arm.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via </span><span
lang=EN-GB style='background:silver'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There is no specific
treatment in the event of overdose of gefitinib. However, in phase I clinical
trials, a limited number of patients were treated with daily doses of up to
1000&nbsp;mg. An increase of frequency and severity of some adverse reactions
was observed, mainly diarrhoea and skin rash. Adverse reactions associated with
overdose should be treated symptomatically; in particular severe diarrhoea
should be managed as clinically indicated. </span><span lang=EN-GB>In one study
a limited number of<b> </b>patients were treated weekly<span style='color:#1F497D'>
</span>with doses from 1500&nbsp;mg<b> </b>to<b> </b>3500&nbsp;mg.<b> </b>In
this study IRESSA exposure did not increase with increasing dose,&nbsp;adverse
events were mostly mild to moderate in severity, and were consistent with the
known safety profile of IRESSA</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: antineoplastic
agents, </span><span lang=EN-GB>protein kinase inhibitors; ATC code: L01XE02</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Mechanism of action and pharmacodynamic
effects</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>The epidermal growth factor (EGF) and its
receptor (EGFR [HER1; ErbB1]) have been identified as key drivers in the
process of cell growth and proliferation for normal and cancer cells. EGFR
activating mutation within a cancer cell is an important factor in promotion of
tumour cell growth, blocking of apoptosis, increasing the production of
angiogenic factors and facilitating the processes of metastasis.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gefitinib is a selective small molecule
inhibitor of the epidermal growth factor receptor tyrosine kinase and is an
effective treatment for patients with tumours with activating mutations of the
EGFR tyrosine kinase domain regardless of line of therapy. No clinically
relevant activity has been shown in patients with known EGFR mutation&#8209;negative
tumours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The common EGFR activating mutations (</span>Exon
19 deletions; L858R<span lang=EN-GB>) have robust response data supporting
sensitivity to gefitinib; for example a progression free survival HR (95% CI)
of 0.489 (0.336, 0.710) for gefitinib vs. doublet chemotherapy [WJTOG3405]. Gefitinib
response data is more sparse in patients whose tumours contain the less common
mutations; the available data indicates that </span><span lang=EN-GB>G719X,
L861Q and S7681 are sensitising mutations; and T790M alone or exon 20
insertions alone are resistance mechanisms.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Resistance</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Most NSCLC tumours with sensitising EGFR
kinase mutations eventually develop resistance to IRESSA treatment, with a
median time to disease progression of 1 year. In about 60% of cases, resistance
is associated with a secondary T790M mutation for which T790M targeted EGFR
TKIs may be considered as a next line treatment option. Other potential mechanisms
of resistance that have been reported following treatment with EGFR signal
blocking agents include: bypass signalling such as HER2 and MET gene amplification
and PIK3CA mutations. Phenotypic switch to small cell lung cancer has also been
reported in 5-10% of cases.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>Circulating
Tumour DNA (ctDNA)</span></i></p>

<p class=MsoNormal><span lang=EN-GB>In the IFUM trial, mutation status was
assessed in tumour and ctDNA samples derived from plasma, using the Therascreen
EGFR RGQ PCR kit (Qiagen). Both ctDNA and tumour samples were evaluable for 652
patients out of 1060 screened. </span><span lang=EN-GB>The objective response
rate (ORR) in those patients who were tumour and ctDNA mutation positive was </span><span
lang=EN-GB>77% (95% CI: 66% to 86%) and in those who were tumour only mutation
positive 60% (95% CI: 44% to 74%).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 2 Summary of baseline mutation
status for tumour and ctDNA samples in all screened patients evaluable for both
samples</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=612
 style='width:459.0pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=134 valign=top style='width:100.3pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Measure</span></b></p>
  </td>
  <td width=233 valign=top style='width:174.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Definition</span></b></p>
  </td>
  <td width=153 valign=top style='width:114.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>IFUM rate </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>% (CI)</span></b></p>
  </td>
  <td width=93 valign=top style='width:69.65pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>IFUM </span></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB>N</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=134 valign=top style='width:100.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Sensitivity</span></p>
  </td>
  <td width=233 valign=top style='width:174.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Proportion of tumour M+ that are M+ by
  ctDNA</span></p>
  </td>
  <td width=153 valign=top style='width:114.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>65.7
  (55.8, 74.7)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=93 valign=top style='width:69.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>105</span></p>
  </td>
 </tr>
 <tr>
  <td width=134 valign=top style='width:100.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Specificity</span></p>
  </td>
  <td width=233 valign=top style='width:174.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>Proportion of tumour M- that are M- by
  ctDNA)</span></p>
  </td>
  <td width=153 valign=top style='width:114.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>99.8
  (99.0, 100.0)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=93 valign=top style='width:69.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>547</span><span
  lang=EN-GB> </span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>These data are consistent with<span
style='color:red'> </span>the pre-planned exploratory Japanese subgroup
analysis in IPASS (Goto 2012). In that study ctDNA derived from serum, not
plasma was used for EGFR mutation analysis using the EGFR Mutation Test Kit
(DxS) (N= 86). In that study, sensitivity was 43.1%, specificity was 100%.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><i><span lang=EN-GB>First line treatment</span></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The randomised
phase III first line IPASS study<b> </b>was conducted in patients in Asia<sup>1</sup>
with advanced (stage IIIB or IV) NSCLC of adenocarcinoma histology who were ex&#8209;light
smokers (ceased smoking <u>&gt;</u>&nbsp;15&nbsp;years ago and smoked <u>&lt;</u>&nbsp;10&nbsp;pack&nbsp;years)
or never smokers</span><span lang=EN-GB> <span style='color:black'>(see
Table&nbsp;3)</span>.</span></p>

<p class=MsoNormal style='text-autospace:none'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB>China,
Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Taiwan and
Thailand.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Table 3 Efficacy outcomes for gefitinib versus
carboplatin/paclitaxel from the IPASS study</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid;height:33.95pt'>
   <td valign=top style='border-top:solid windowtext 1.5pt;border-left:none;
   border-bottom:solid windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;
   height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Population</span></b></p>
   </td>
   <td width=52 valign=top style='width:39.05pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>N</span></b></p>
   </td>
   <td width=130 valign=top style='width:97.15pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Objective response rates and 95% CI for difference between
   treatments<sup>a</sup></span></b></p>
   </td>
   <td width=186 valign=top style='width:139.7pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Primary endpoint</span></b></p>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Progression free survival (PFS) <sup>a,b</sup></span></b></p>
   </td>
   <td width=124 valign=top style='width:92.7pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Overall survival<sup>a,b</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:81.7pt'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:81.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Overall</span></p>
  </td>
  <td width=52 valign=top style='width:39.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:81.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1217</span></p>
  </td>
  <td width=130 valign=top style='width:97.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:81.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>43.0%
  vs 32.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[5.3%,
  16.1%]</span></p>
  </td>
  <td width=186 valign=top style='width:139.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:81.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.74</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.65,
  0.85]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>5.7&nbsp;m
  vs 5.8&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p&lt;0.0001</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:81.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.90</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.79,
  1.02]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>18.8&nbsp;m
  vs 17.&nbsp;4m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.1087</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>EGFR
  mutation&#8209;positive</span></p>
  </td>
  <td width=52 valign=top style='width:39.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>261</span></p>
  </td>
  <td width=130 valign=top style='width:97.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>71.2%
  vs 47.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[12.0%,
  34.9%]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=186 valign=top style='width:139.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.48</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.36,
  0.64]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>9.5&nbsp;m
  vs 6.3&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p&lt;0.0001</span></p>
  <p class=MsoNormal align=center style='text-align:center'><s><span lang=SV><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.00</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.76,
  1.33]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>21.6&nbsp;m
  vs 21.9&nbsp;m</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>EGFR
  mutation&#8209;negative</span></p>
  </td>
  <td width=52 valign=top style='width:39.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>176</span></p>
  </td>
  <td width=130 valign=top style='width:97.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1.1%
  vs 23.5%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[&#8209;32.5%,
  &#8209;13.3%]</span></p>
  </td>
  <td width=186 valign=top style='width:139.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  2.85</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[2.05,
  3.98]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1.5&nbsp;m
  vs 5.5&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p&lt;0.0001</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.18</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.86,
  1.63]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>11.2&nbsp;m
  vs 12.7&nbsp;m</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>EGFR
  mutation-unknown</span></p>
  </td>
  <td width=52 valign=top style='width:39.05pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>780</span></p>
  </td>
  <td width=130 valign=top style='width:97.15pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>43.3%
  vs 29.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>[7.3%,
  20.6%]</span></p>
  </td>
  <td width=186 valign=top style='width:139.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HR
  0.68</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>[0.58
  to 0.81]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>6.6</span><span
  lang=SV>&nbsp;m vs 5.8&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p&lt;0.0001</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HR
  0.82</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>[0.70
  to 0.96] 18.9&nbsp;m vs. 17.2&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>a</span></sup><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Values
presented are for IRESSA versus carboplatin/paclitaxel.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><sup><span
lang=EN-GB style='font-size:10.0pt'>b</span></sup><span lang=EN-GB
style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#8220;m&#8221;
is medians in months. Numbers in square brackets are 95% confidence intervals
for HR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number
of patients randomised.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>HR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard
ratio (hazard ratios &lt;1&nbsp;favour IRESSA)</span></p>

<p class=MsoNormal><s><span lang=EN-GB style='font-size:10.0pt'><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span lang=EN-GB>Quality of life outcomes differed according
to EGFR mutation status. In EGFR mutation&#8209;positive patients,
significantly more IRESSA&#8209;treated patients experienced an improvement in
quality of life and lung cancer symptoms vs. carboplatin/paclitaxel (see
Table&nbsp;4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 4 Quality of life outcomes for
gefitinib versus carboplatin/paclitaxel from the IPASS study</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid;height:33.95pt'>
   <td valign=top style='border-top:solid windowtext 1.5pt;border-left:none;
   border-bottom:solid windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;
   height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>Population</span></b></p>
   </td>
   <td valign=top style='border-top:solid windowtext 1.5pt;border-left:none;
   border-bottom:solid windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt;
   height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>N</span></b></p>
   </td>
   <td width=216 valign=top style='width:161.65pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>FACT&#8209;L QoL improvement rate<sup>a</sup> <br>
   %</span></b></p>
   </td>
   <td width=215 valign=top style='width:161.25pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt;height:33.95pt'>
   <p class=MsoNormal align=center style='text-align:center'><b><span
   lang=EN-GB>LCS symptom improvement rate<sup> a</sup> %</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:33.7pt'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:33.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Overall</span></p>
  </td>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:33.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1151</span></p>
  </td>
  <td width=216 valign=top style='width:161.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:33.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(48.0%
  vs 40.8%)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.0148</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=215 valign=top style='width:161.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:33.7pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(51.5%
  vs 48.5%)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.3037</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>EGFR
  mutation&#8209;positive</span></p>
  </td>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>259</span></p>
  </td>
  <td width=216 valign=top style='width:161.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(70.2%
  vs 44.5%)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p&lt;0.0001</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=215 valign=top style='width:161.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(75.6%
  vs 53.9%)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.0003</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>EGFR
  mutation&#8209;negative</span></p>
  </td>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>169</span></p>
  </td>
  <td width=216 valign=top style='width:161.65pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(14.6%
  vs 36.3%)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.0021</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=215 valign=top style='width:161.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(20.2%
  vs 47.5%)</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.0002</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>Trial outcome
index results were supportive of FACT&#8209;L and LCS results</span></p>

<p class=MsoNormal><sup><span lang=EN-GB style='font-size:10.0pt'>a</span></sup><span
lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Values
presented are for IRESSA versus carboplatin/paclitaxel.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number
of patients evaluable for quality of life analyses</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>QoL&nbsp;&nbsp;&nbsp;&nbsp; Quality of life</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>FACT&#8209;L Functional assessment of
cancer therapy&#8209;lung</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>LCS&nbsp;&nbsp;&nbsp;&nbsp; Lung
cancer subscale</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the IPASS trial, IRESSA demonstrated
superior PFS, ORR, QoL and symptom relief with no significant difference in
overall survival compared to carboplatin/paclitaxel in previously untreated
patients, with locally advanced or metastatic NSCLC, whose tumours harboured
activating mutations of the EGFR tyrosine kinase.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Pretreated patients</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The randomised phase III INTEREST study was
conducted in patients with locally advanced or metastatic NSCLC who had
previously received platinum&#8209;based chemotherapy. </span><span lang=EN-GB
style='color:black'>In the overall population, no statistically significant
difference between gefitinib and docetaxel (75&nbsp;mg/m<sup>2</sup>) was
observed for overall survival, progression free survival and objective response
rates (see Table&nbsp;5).</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 5
Efficacy outcomes for gefitinib versus docetaxel from the INTEREST study</span></b></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=619 colspan=5 valign=top style='width:464.35pt;border:none;
   border-top:solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Population</span></b></p>
   </td>
   <td width=52 valign=top style='width:39.1pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB><br>
   N</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.35pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Objective response rates and 95% CI for
   difference between treatments<sup>a</sup></span></b></p>
   </td>
   <td width=193 valign=top style='width:144.45pt;border:none;border-bottom:
   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Progression free survival<sup>ab</sup></span></b></p>
   </td>
   <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Primary endpoint overall survival<sup>ab</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Overall</span></p>
  </td>
  <td width=52 valign=top style='width:39.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1466</span></p>
  </td>
  <td width=123 valign=top style='width:92.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>9.1% vs 7.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>[&#8209;1.5%, 4.5%]</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=193 valign=top style='width:144.45pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>HR 1.04</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>[0.93,1.18]</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>2.2&nbsp;m vs 2.7&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>p=0.4658</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>HR 1.020</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>[0.905, 1.150]<sup> c</sup></span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>7.6&nbsp;m vs 8.0&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=SV>p=0.7332</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>EGFR
  mutation&#8209;positive</span></p>
  </td>
  <td width=52 valign=top style='width:39.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>44</span></p>
  </td>
  <td width=123 valign=top style='width:92.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>42.1%
  vs 21.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[&#8209;8.2%,
  46.0%]</span></p>
  </td>
  <td width=193 valign=top style='width:144.45pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.16</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.05,
  0.49]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>7.0&nbsp;m
  vs 4.1&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.0012</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.83</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.41,
  1.67]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>14.2&nbsp;m
  vs 16.6&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.6043</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>EGFR
  mutation&#8209; negative</span></p>
  </td>
  <td width=52 valign=top style='width:39.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>253</span></p>
  </td>
  <td width=123 valign=top style='width:92.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>6.6%
  vs 9.8%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[&#8209;10.5%,
  4.4%]</span></p>
  </td>
  <td width=193 valign=top style='width:144.45pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.24</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.94,1.64]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1.7&nbsp;m
  vs 2.6&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.1353</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.02</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.78,
  1.33]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>6.4&nbsp;m
  vs 6.0&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.9131</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Asians<sup>c</sup></span></p>
  </td>
  <td width=52 valign=top style='width:39.1pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>323</span></p>
  </td>
  <td width=123 valign=top style='width:92.35pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>19.7%
  vs 8.7%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[3.1&nbsp;%,
  19.2%]</span></p>
  </td>
  <td width=193 valign=top style='width:144.45pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.83</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.64,1.08]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>2.9&nbsp;m
  vs 2.8&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.1746</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.04</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.80,
  1.35]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>10.4&nbsp;m
  vs 12.2&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.7711</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Non&#8209;Asians</span></p>
  </td>
  <td width=52 valign=top style='width:39.1pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1143</span></p>
  </td>
  <td width=123 valign=top style='width:92.35pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>6.2%
  vs 7.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[&#8209;4.3%,
  2.0%]</span></p>
  </td>
  <td width=193 valign=top style='width:144.45pt;border:none;border-bottom:
  solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR 1.12</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.98,
  1.28]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>2.0&nbsp;m
  vs 2.7&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.1041</span></p>
  </td>
  <td width=124 valign=top style='width:92.7pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.01</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.89,
  1.14]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>6.9&nbsp;m
  vs 6.9&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.9259</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Values
presented are for IRESSA versus docetaxel.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>b</span><span lang=EN-GB style='font-size:
10.0pt'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#8220;m&#8221; is
medians in months. Numbers in square brackets are 96% confidence interval for
overall survival HR in the overall population, or otherwise 95% confidence
intervals for HR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confidence
interval entirely below non&#8209;inferiority margin of 1.154</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number
of patients randomised.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>HR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard
ratio (hazard ratios &lt;1 favour IRESSA)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

<i><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></i>

<div class=WordSection2>

<p class=MsoNormal><b><span lang=EN-GB>Figures 1 and 2 Efficacy outcomes in subgroups
of non&#8209;Asian patients in the INTEREST study</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>(N patients = Number of patients randomised)</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB><img border=0 width=573 height=666
src="Iressa%20II-34-%20EN%20PI%20-%20clea_files/image001.gif"></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The randomised phase III ISEL study was
conducted in patients with advanced NSCLC who had received 1 or 2 prior
chemotherapy regimens and were refractory or intolerant to their most recent
regimen. Gefitinib plus best supportive care was compared to placebo plus best
supportive care. IRESSA did not prolong survival in the overall population.
Survival outcomes differed by smoking status and ethnicity (see Table&nbsp;6).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Table 6
Efficacy outcomes for gefitinib versus placebo from the ISEL study</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td valign=top style='border-top:solid windowtext 1.5pt;border-left:none;
   border-bottom:solid windowtext 1.5pt;border-right:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Population</span></b></p>
   </td>
   <td width=52 valign=top style='width:39.3pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB><br>
   N</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.3pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Objective
   response rates and 95% CI for difference between treatments<sup>a</sup></span></b></p>
   </td>
   <td width=192 valign=top style='width:144.35pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Time
   to treatment failure<sup>ab</sup></span></b></p>
   </td>
   <td width=124 valign=top style='width:92.65pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.5pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Primary
   endpoint overall survival<sup>abc</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Overall</span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1692</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>8.0%
  vs 1.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>[4.7%,
  8.8%]</span></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>HR
  0.82</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.73,
  0.92]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>3.0&nbsp;m
  vs 2.6&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.0006</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.89</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.77,1.02]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>5.6&nbsp;m
  vs 5.1&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.0871</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>EGFR
  mutation&#8209; positive</span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>26</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>37.5%
  vs 0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[&#8209;15.1%,
  61.4%]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.79</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.20,
  3.12]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>10.8&nbsp;m
  vs 3.8m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.7382</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR NC</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>&nbsp;</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>NR vs
  4.3&nbsp;m</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>EGFR
  mutation&#8209; negative</span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>189</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>2.6%
  vs 0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[&#8209;5.6%,
  7.3%]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><s><span lang=SV><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.10</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.78,
  1.56]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>2.0&nbsp;m
  vs 2.6&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.5771</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  1.16</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.79,
  1.72]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>3.7&nbsp;m
  vs 5.9&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.4449</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Never
  smoker</span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>375</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>18.1%
  vs 0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[12.3&nbsp;%,
  24.0%]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><s><span lang=SV><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.55</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.42,
  0.72]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>5.6&nbsp;m
  vs 2.8&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p&lt;0.0001</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.67</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.49,
  0.92]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>8.9&nbsp;m
  vs 6.1&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.0124</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Ever
  smoker</span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1317</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>5.3%
  vs 1.6%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[1.4%,
  5.7%]</span></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.89</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.78,
  1.01]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>2.7&nbsp;m
  vs 2.6&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.0707</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.92</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.79,
  1.06]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>5.0&nbsp;m
  vs 4.9&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.2420</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Asians<sup>d</sup></span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>342</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>12.4%
  vs 2.1%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[4.0%,
  15.8%]</span></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.69</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.52,
  0.91]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>4.4&nbsp;m
  vs 2.2&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.0084</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.66</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.48,
  0.91]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>9.5&nbsp;m
  vs 5.5&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.0100</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td valign=top style='border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Non&#8209;Asians</span></p>
  </td>
  <td width=52 valign=top style='width:39.3pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>1350</span></p>
  </td>
  <td width=123 valign=top style='width:92.3pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>6.8%
  vs 1.0%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[3.5%,
  7.9%]</span></p>
  </td>
  <td width=192 valign=top style='width:144.35pt;border:none;border-bottom:
  solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.86</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.76,
  0.98]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>2.9&nbsp;m
  vs 2.7&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>p=0.0197</span></p>
  </td>
  <td width=124 valign=top style='width:92.65pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>HR
  0.92</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>[0.80,
  1.07]</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=SV>5.2&nbsp;m
  vs 5.1&nbsp;m</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>p=0.2942</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Values
presented are for IRESSA versus placebo.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB style='font-size:10.0pt'>&#8220;m&#8221; is medians in months. Numbers
in square brackets are 95% confidence intervals for HR</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stratified
log&#8209;rank test for overall; otherwise cox proportional hazards model</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asian
ethnicity excludes patients of Indian origin and refers to the racial origin of
a patient group and not necessarily their place of birth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>N&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number
of patients randomised</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>NC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not
calculated for overall survival HR as the number of events is too few</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>NR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not
reached</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:10.0pt'>HR&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard
ratio (hazard ratios &lt;1 favour IRESSA)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The IFUM study was a single-arm, multicentre study conducted
in Caucasian patients (n=106) with activating, sensitising EGFR mutation
positive NSCLC to confirm that the activity of gefitinib is similar in
Caucasian and Asian populations. The ORR according to investigator review was
70% and the median PFS was 9.7 months. These data are similar to those reported
in the IPASS study.</p>

<p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>EGFR mutation status and clinical
characteristics</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Clinical characteristics of never smoker,
adenocarcinoma histology, and female gender have been shown to be independent
predictors of positive EGFR mutation status in a multivariate analysis of
786&nbsp;Caucasian patients from gefitinib studies* (see Table&nbsp;7). Asian
patients also have a higher incidence of EGFR mutation&#8209;positive tumours.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:4.5pt;text-indent:-4.5pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>Table 7 Summary of
multivariate logistic regression analysis to identify factors that independently
predicted for the presence of EGFR mutations in 786 Caucasian patients*</span></b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=117 valign=top style='width:87.9pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Factors that predicted for presence of EGFR
   mutation</span></b></p>
   </td>
   <td width=73 valign=top style='width:55.0pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>p&#8209;value</span></b></p>
   </td>
   <td width=161 valign=top style='width:121.0pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Odds of EGFR mutation</span></b></p>
   </td>
   <td width=269 valign=top style='width:201.95pt;border-top:solid windowtext 1.5pt;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB>Positive predictive value (9.5% of the overall
   population are EGFR mutation&#8209;positive (M+))</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:87.9pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>Smoking status</span></p>
  </td>
  <td width=73 valign=top style='width:55.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>6.5&nbsp;times higher in never smokers than ever&#8209;smokers</span></p>
  </td>
  <td width=269 valign=top style='width:201.95pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>28/70 (40%) of never smokers are M+ <br>
  47/716 (7%) of ever smokers are M+</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:87.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Histology</span></p>
  </td>
  <td width=73 valign=top style='width:55.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&lt;0.0001</span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>4.4&nbsp;times
  higher in adenocarcinoma than in non&#8209;adenocarcinoma</span></p>
  </td>
  <td width=269 valign=top style='width:201.95pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>63/396
  (16%) of patients with adenocarcinoma histology are M+<br>
  12/390 (3%) of patients with non&#8209;adenocarcinoma histology are M+</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=117 valign=top style='width:87.9pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>Gender</span></p>
  </td>
  <td width=73 valign=top style='width:55.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>0.0397</span></p>
  </td>
  <td width=161 valign=top style='width:121.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>1.7&nbsp;times
  higher in females than males</span></p>
  </td>
  <td width=269 valign=top style='width:201.95pt;border:none;border-bottom:
  solid windowtext 1.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>40/235
  (17%) of females are M+<br>
  35/551 (6%) of males are M+</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>*from the
following studies: INTEREST, ISEL, INTACT 1&amp;2, IDEAL 1&amp;2, INVITE</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Following oral
administration of gefitinib, absorption is moderately slow and peak plasma
concentrations of gefitinib typically occur at 3 to 7&nbsp;hours after
administration. Mean absolute bioavailability is 59% in cancer patients.
Exposure to gefitinib is not significantly altered by food. In a trial in
healthy volunteers where gastric pH was maintained above pH</span><span
lang=EN-GB>&nbsp;5, gefitinib exposure was reduced by 47%, likely due to
impaired solubility of gefitinib in the stomach (see sections&nbsp;4.4 and
4.5).</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Gefitinib has a
mean steady-state volume of distribution of 1400&nbsp;l indicating extensive
distribution into tissue. Plasma protein binding is approximately 90%.
Gefitinib binds to serum albumin and alpha 1&#8209;acid glycoprotein.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> data indicate that gefitinib is a substrate for the membrane
transport protein P-gp.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> data indicate that CYP3A4 and CYP2D6 are the major P450 isozyme
involved in the oxidative metabolism of gefitinib.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies have shown that gefitinib has limited potential to inhibit
CYP2D6. Gefitinib shows no enzyme induction effects in animal studies and no
significant inhibition (</span><i><span lang=EN-GB>in vitro</span></i><span
lang=EN-GB>) of any other cytochrome P450 enzyme.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Gefitinib is
extensively metabolised in humans. Five metabolites have been fully identified
in excreta and 8&nbsp;metabolites in plasma. The major metabolite identified
was O&#8209;desmethyl gefitinib, which is 14&#8209;fold less potent than
gefitinib at inhibiting EGFR stimulated cell growth and has no inhibitory
effect on tumour cell growth in mice. It is therefore considered unlikely that
it contributes to the clinical activity of gefitinib.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>The formation of
O&#8209;desmethyl gefitinib has been shown, </span><i><span lang=EN-GB>in vitro</span></i><span
lang=EN-GB>, to be via CYP2D6. The role of CYP2D6 in the metabolic clearance of
gefitinib has been evaluated in a clinical trial in healthy volunteers
genotyped for CYP2D6 status. In poor metabolisers no measurable levels of O&#8209;desmethyl
gefitinib were produced. The levels of exposure to gefitinib achieved in both
the extensive and the poor metaboliser groups were wide and overlapping but the
mean exposure to gefitinib was 2&#8209;fold higher in the poor metaboliser
group. The higher average exposures that could be achieved by individuals with
no active CYP2D6 may be clinically relevant since adverse effects are related
to dose and exposure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='margin-right:-.1pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><span lang=EN-GB>Gefitinib is excreted mainly as metabolites
via the faeces, with renal elimination of gefitinib and metabolites accounting
for less than 4% of the administered dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Gefitinib total
plasma clearance is approximately 500&nbsp;ml/min and the mean terminal half&#8209;life
is 41&nbsp;hours in cancer patients. Administration of gefitinib once daily
results in 2- to 8&#8209;fold accumulation, with steady state exposures
achieved after 7 to 10&nbsp;doses. At steady state, circulating plasma
concentrations are typically maintained within a 2&#8209; to 3&#8209;fold range
over the 24&#8209;hour dosing interval.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>Special
populations</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>From analyses of
population pharmacokinetic data in cancer patients, no relationships were
identified between predicted steady-state trough concentration and patient age,
body weight, gender, ethnicity or creatinine clearance </span><span lang=EN-GB>(above
20</span><span lang=EN-GB>&nbsp;</span><span lang=EN-GB>ml/min)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><i><span lang=EN-GB>Hepatic
impairment</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>In a phase I
open&#8209;label study of single dose gefitinib 250</span><span lang=EN-GB>&nbsp;mg
in patients with mild, moderate or severe hepatic impairment due to cirrhosis
(according to Child&#8209;Pugh classification), there was an increase in
exposure in all groups compared with healthy controls. An average 3.1&#8209;fold
increase in exposure to gefitinib in patients with moderate and severe hepatic
impairment was observed. None of the patients had cancer, all had cirrhosis and
some had hepatitis. This increase in exposure may be of clinical relevance
since adverse experiences are related to dose and exposure to gefitinib.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Gefitinib has
been evaluated in a clinical trial conducted in 41 patients with solid tumours
and normal hepatic function, or moderate or severe hepatic impairment
(classified according to baseline Common Toxicity Criteria grades for AST,
alkaline phosphatase and bilirubin) due to liver metastases. It was shown that
following daily administration of 250</span><span lang=EN-GB>&nbsp;mg
gefitinib, time to steady-state, total plasma clearance (C<sub>maxSS</sub>) and
steady-state exposure (AUC<sub>24SS</sub>) were similar for the groups with
normal and moderately impaired hepatic function. Data from 4&nbsp;patients with
severe hepatic impairment due to liver metastases suggested that steady&#8209;state
exposures in these patients are also similar to those in patients with normal
hepatic function.</span></p>

<p class=MsoNormal style='margin-bottom:6.0pt;text-align:justify;text-justify:
inter-ideograph'><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions not observed in clinical
studies, but seen in animals at exposure levels similar to the clinical
exposure levels and with possible relevance to clinical use were as follows:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Corneal epithelia atrophy and corneal
translucencies</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Renal papillary necrosis</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hepatocellular necrosis and eosinophilic
sinusoidal macrophage infiltration</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Data from non-clinical (<i>in vitro</i>)
studies indicate that gefitinib has the potential to inhibit the cardiac action
potential repolarisation process (e.g. QT interval). Clinical experience has
not shown a causal association between QT prolongation and gefitinib.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A reduction in female fertility was
observed in the rat at a dose of 20&nbsp;mg/kg/day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Published studies have shown that
genetically modified mice, lacking expression of EGFR, exhibit developmental
defects, related to epithelial immaturity in a variety of organs including the
skin, gastrointestinal tract and lung. When gefitinib was administered to rats
during organogenesis, there were no effects on embryofoetal development at the
highest dose (30&nbsp;mg/kg/day). However, in the rabbit, there were reduced
foetal weights at 20&nbsp;mg/kg/day and above. There were no compound&#8209;induced
malformations in either species. When administered to the rat throughout
gestation and parturition, there was a reduction in pup survival at a dose of
20&nbsp;mg/kg/day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Following oral
administration of C&#8209;14 labelled gefitinib to lactating rats 14 days post-partum,
concentrations of radioactivity in milk were 11&#8209;19&nbsp;fold higher than
in blood.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Gefitinib showed no genotoxic potential.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>A 2&#8209;year carcinogenicity study in
rats resulted in a small but statistically significant increased incidence of
hepatocellular adenomas in both male and female rats and mesenteric lymph node
haemangiosarcomas in female rats at the highest dose (10&nbsp;mg/kg/day) only.
The hepatocellular adenomas were also seen in a 2&#8209;year carcinogenicity
study in mice, which demonstrated a small increased incidence of this finding
in male mice at the mid dose, and in both male and female mice at the highest
dose. The effects reached statistical significance for the female mice, but not
for the males. At no&#8209;effect levels in both mice and rats there was no
margin in clinical exposure. The clinical relevance of these findings is
unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The results of an <i>in vitro</i>
phototoxicity study demonstrated that gefitinib may have phototoxicity
potential.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><i><span lang=EN-GB>Tablet core</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Lactose monohydrate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Microcrystalline cellulose (E460)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Croscarmellose sodium</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Povidone (</span><span lang=EN-GB>K29&#8209;32</span><span
lang=EN-GB>) (E1201)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Sodium laurilsulfate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Magnesium stearate</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><i><span lang=EN-GB>Tablet coating</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Hypromellose (E464)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Macrogol 300</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Titanium dioxide (E171)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Yellow iron oxide (E172)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>Red iron oxide (E172)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the
original package in order to protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>PVC/Aluminium perforated blister containing 10 tablets or
PVC/Aluminium non-perforated blister containing 10 tablets.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Three&nbsp;blisters are combined with an aluminium foil laminate
over-wrap in a carton.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pack size of
30&nbsp;film-coated tablets.</span><span lang=EN-GB style='font-size:12.0pt'> </span><span
lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a
name="OLE_LINK1"><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></a></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
HOLDER</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>AstraZeneca AB</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SE&#8209;151 85</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>S&ouml;dert&auml;lje
</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>Sweden</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=SV>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>EU/1/09/526/001 perforated blister</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>EU/1/09/526/002 non
perforated blister</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first
authorisation: 24 June 2009</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 23 April 2014</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF
REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>Detailed information on this product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency <span
style='color:blue'><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.55pt'><b><span
lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.55pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.55pt'><b><span
lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=A-Heading1 align=left style='margin-left:.5in;text-align:left;
text-indent:-.5in'><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:70.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Name and
address of the manufacturers responsible for batch release</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>AstraZeneca AB</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>G&auml;rtunav&auml;gen</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>SE&#8209;151 85
S&ouml;dert&auml;lje</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>Sweden</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>AstraZeneca UK
Limited</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Macclesfield</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>Cheshire SK10
2NA</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>United Kingdom</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=LV>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=LV>The printed package
leaflet of the medicinal product must state the name and address of the
manufacturer responsible for the release of the concerned batch.</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=A-Heading1 align=left style='text-align:left'><a name="OLE_LINK2"><span
lang=EN-GB>B.</span></a><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription</span><span lang=EN-GB> (See
Annex I: Summary of Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=A-Heading1 align=left style='margin-left:.5in;text-align:left;
text-indent:-.5in'>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The marketing
authorisation holder (MAH) shall submit PSURs for this product in accordance
with the requirements set out in the list of Union reference dates (EURD list)
provided for under Article 107c(7) of Directive 2001/83</span><span lang=EN-GB>/EC</span><span
lang=EN-GB> and published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=A-Heading1 align=left style='text-align:left'><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EFFECTIVE
USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-31.5pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt'><span lang=EN-GB>The marketing
authoridsation holder (MAH) shall perform the required pharmacovigilance
activities and interventions detailed in the agreed RMP presented in Module
1.8.2 of the marketing authorisation and any agreed subsequent updates of the
RMP.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>An updated RMP
shall be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:31.5pt;margin-bottom:.0001pt;text-indent:-13.5pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>If the dates
for submission of a PSUR and the update of a RMP coincide, they can be
submitted at the same time.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:green'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=A-Heading1><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF
THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IRESSA
250&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>gefitinib</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 250&nbsp;mg gefitinib.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST OF
EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains lactose
and sodium, see package leaflet for further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>30&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Store in the original
package in order to protect from moisture.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>AstraZeneca AB</span></p>

<p class=MsoNormal><span lang=EN-GB>SE&#8209;151 85</span></p>

<p class=MsoNormal><span lang=EN-GB>S&ouml;dert&auml;lje</span></p>

<p class=MsoNormal><span lang=EN-GB>Sweden</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'>EU/1/09/526/001 <span
style='background:silver'>perforated blister </span></p>

<p class=MsoNormal style='line-height:normal'><span style='background:silver'>EU/1/09/526/002
non perforated blister </span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</b></p>

</div>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to medical
prescription.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>iressa</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER &#8211; 2D
BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>&lt;2D barcode carrying the unique identifier
included.&gt;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC </span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR
STRIPS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BLISTER/ALUMINIUM FOIL LAMINATE FLOW WRAP</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'>IRESSA 250&nbsp;mg tablets</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'>gefitinib</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>AstraZeneca</span></p>

<p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=A-Heading1><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the patient</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB style='text-transform:uppercase'>IRESSA</span><span lang=EN-GB> 250</span></b><span
lang=EN-GB>&nbsp;<b>mg film&#8209;coated tablets</b></span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>gefitinib</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine because it contains
important information for you.</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:35.45pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects not listed
in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b><span lang=EN-GB>:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What <span
style='text-transform:uppercase'>IRESSA</span> is and what it is used for</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to
know before you take<span style='text-transform:uppercase'> IRESSA</span></span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take <span
style='text-transform:uppercase'>IRESSA</span></span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store <span
style='text-transform:uppercase'>IRESSA</span></span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;line-height:normal'><b><span
lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What IRESSA is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>IRESSA</span><span
lang=EN-GB> contains the active substance gefitinib which blocks a </span><span
lang=EN-GB>protein called &#8216;epidermal growth factor receptor&#8217;
(EGFR). This protein is involved in the growth and spread of cancer cells.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>IRESSA is used to treat adults with non&#8209;small
cell lung cancer. This cancer is a disease in which malignant (cancer) cells
form in the tissues of the lung.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><b><span
lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>What you need to know before you take IRESSA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not take <span
style='text-transform:uppercase'>IRESSA</span></span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to gefitinib or any of the
other ingredients of this medicine (listed in section&nbsp;6, &#8216;What IRESSA
contains&#8217;).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are breast&#8209;feeding.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Talk to your doctor or pharmacist before taking <span
style='text-transform:uppercase'>IRESSA</span></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had any other lung problems.
Some lung problems may get worse during treatment with <span style='text-transform:
uppercase'>IRESSA</span>.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have ever had problems with your liver.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>IRESSA</span><span lang=EN-GB> is not indicated in children and
adolescents under 18&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and IRESSA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken, or might take any other medicines.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>In particular, tell your doctor or pharmacist if you are taking any
of the following medicines:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Phenytoin or carbamazepine (for epilepsy).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rifampicin (for tuberculosis).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Itraconazole (for fungal infections).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Barbiturates (a type of medicine used for
sleeping problems).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Herbal remedies containing St John&#8217;s wort
(<i>Hypericum perforatum</i>, used for depression and anxiety).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Proton&#8209;pump inhibitors, H<sub>2</sub>&#8209;antagonists
and antacids (for ulcers, indigestion, heartburn and to reduce acids in the
stomach).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>These medicines may affect the way IRESSA works.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Warfarin (a so&#8209;called oral anticoagulant,
to prevent blood clots). If you are taking a medicine containing this active
substance, your doctor may need to do blood tests more often.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If any of the above applies to you, or if you are not sure, check with
your doctor or pharmacist before taking <span style='text-transform:uppercase'>IRESSA</span>.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Pregnancy, breast-feeding and fertility</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Talk to your
doctor before taking this medicine if you are pregnant, may become pregnant or
are breast-feeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is
recommended that you avoid becoming pregnant during treatment with IRESSA
because IRESSA could harm your baby.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not take IRESSA
if you are breast-feeding. This is for the safety of your baby.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>You may feel
weak while taking treatment with Iressa. If this happens, do not drive or use
any tools or machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>IRESSA</span></b><b><span lang=EN-GB style='font-family:"Times New Roman Bold",serif;
text-transform:uppercase'> </span><span lang=EN-GB>contains lactose</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have been told by your doctor that you have an intolerance to
some sugars, contact your doctor before taking this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>IRESSA contains sodium</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>This medicine contains less than 1 mmol (23 mg) of sodium per dose,
that is to say it is essentially &#8216;sodium-free&#8217;.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><b><span
lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-GB>How to take IRESSA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you. Check
with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The recommended dose is one 250&nbsp;mg tablet
per day.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Take the tablet at about the same time each day.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You can take the tablet with or without food.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not take antacids (to reduce the acid level
of your stomach) 2&nbsp;hours before or 1&nbsp;hour after taking IRESSA.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have trouble swallowing the tablet, dissolve it in half a
glass of still (non-fizzy) water. Do not use any other liquids. Do not crush
the tablet. Swirl the water until the tablet has dissolved. This may take up to
20&nbsp;minutes. Drink the liquid straight away. To make sure that you have
drunk all of the medicine, rinse the glass very well with half a glass of water
and drink it.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you take more </span></b><b><span lang=EN-GB>IRESSA</span><span
lang=EN-GB style='text-transform:uppercase'> </span><span lang=EN-GB>than you
should</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have taken more tablets than you should, talk to a doctor or
pharmacist straight away.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>If you forget to take</span></b><b><span lang=EN-GB> IRESSA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>What to do if you forget to take a tablet depends on how long it is
until your next dose.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If it is 12&nbsp;hours or more until your next
dose:<b> </b>take the missed tablet as soon as you remember. Then take the next
dose as usual.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If it is less than 12&nbsp;hours until your next
dose:<b> </b>skip the missed tablet. Then take the next tablet at the usual
time.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take a double dose (two tablets at
the same time) to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines this medicine<span style='text-transform:uppercase'>
</span>can cause side effects, although not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Tell your doctor immediately if you notice any of the following side
effects &#8209; you may need urgent medical treatment:</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Allergic reaction (common), particularly if
symptoms include<b><i> </i></b>swollen face, lips, tongue or throat, difficulty
to swallow, hives, nettle rash and difficulty breathing.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Serious breathlessness, or sudden worsening
breathlessness, possibly with a cough or fever. This may mean that you have an
inflammation of the lungs called &#8216;interstitial lung disease&#8217;. This
may affect about 1 in 100&nbsp;patients taking IRESSA and can be life&#8209;threatening.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Severe skin reactions (rare) affecting large
areas of your body. The signs may include redness, pain, ulcers, blisters, and
shedding of the skin. The lips, nose, eyes and genitals may also be affected.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dehydration (common) caused by long term or
severe diarrhoea, vomiting (being sick), nausea (feeling sick) or loss of
appetite.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Eye problems (uncommon), such as pain, redness</span><span
lang=EN-GB>, watery eyes, light sensitivity, changes in vision or ingrowing
eyelashes. This may mean that you have an ulcer on the surface of the eye
(cornea).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell your doctor as soon as possible if you notice any of the following
side effects:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common</span></b><span lang=EN-GB>: <b>may affect more than 1
in 10 people</b></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Vomiting</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Skin reactions such as an acne-like rash, which
is sometimes itchy with dry </span><span lang=EN-GB>and/or cracked skin</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Loss of appetite</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Weakness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Red or sore mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increase of a liver enzyme known as alanine
aminotransferase in a blood test; if too high, your doctor may tell you to stop
taking IRESSA</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common: may affect up to 1 in 10 people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dry mouth</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dry, red or itchy eyes</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Red and sore eyelids</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nail problems</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hair loss</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Fever</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Bleeding (such as nose bleed or blood in your
urine)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Protein in your urine (shown in a urine test)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increase of bilirubin and the other liver enzyme
known as aspartate aminotransferase in a &nbsp;&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;&nbsp; blood test; if too high, your doctor may
tell you to stop taking IRESSA</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Increase of creatinine levels in a blood test
(related to kidney function)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Cystitis (b</span><span
lang=EN-GB>urning sensations during urination and frequent, urgent need to
urinate</span><span lang=EN-GB style='color:black'>)</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Uncommon: </span></b><b><span lang=EN-GB>may affect up to 1 in 100
people</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the pancreas. The signs include
very severe pain in the upper part of the stomach area and severe nausea and
vomiting.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the liver. Symptoms may include
a general feeling of being unwell, with or without possible jaundice (yellowing
of the skin and eyes). This side effect is uncommon; however, some patients
have died from this.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gastrointestinal perforation</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;Skin reaction on the palms of
the hands and soles of the feet including tingling, numbness, pain, swelling or
reddening (known as palmar-plantar erythrodysaesthesia syndrome or hand and
foot syndrome).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Rare: may affect up to 1 in 1000 people</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the blood vessels in the skin.
This may give the appearance of bruising or patches of non-blanching rash on
the skin.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>Haemo</span><span
lang=EN-GB style='color:black'>rrhagic </span><span lang=EN-GB
style='color:black'>cystitis (</span><span lang=EN-GB>burning sensations during
urination and frequent, urgent need to urinate <span style='color:black'>with
blood in the urine).</span></span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, </span><span lang=EN-GB>talk to your
doctor, pharmacist, or nurse. </span><span lang=EN-GB>This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:silver'>the national reporting
system listed in </span><span style='background:silver'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix
V</a></span>. By reporting side effects you can help provide more information
on the safety of this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store IRESSA</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not use this medicine after the expiry
date which is stated on the carton, blister and overwrap foil after EXP. The
expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in the original package in order to
protect from moisture.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not </span><span lang=EN-GB>throw away
any medicines </span><span lang=EN-GB>via wastewater or household waste. Ask
your pharmacist how to </span><span lang=EN-GB>throw away </span><span
lang=EN-GB>medicines you no longer use. </span><span lang=EN-GB>These measures
will help to protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>IRESSA</span><span lang=EN-GB>
contains</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The active substance is gefitinib. Each tablet
contains 250&nbsp;mg of gefitinib.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients (excipients) are lactose
monohydrate, microcrystalline cellulose (E460), croscarmellose sodium, povidone
(K29&#8209;32) (E1201), sodium laurilsulfate, magnesium stearate, hypromellose
(E464), macrogol 300, titanium dioxide (E171), yellow iron oxide (E172) and red
iron oxide (E172).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What </span></b><b><span lang=EN-GB>IRESSA</span><span lang=EN-GB>
looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='text-transform:uppercase'>IRESSA</span><span lang=EN-GB> is a
round brown tablet marked with &#8216;IRESSA 250&#8217; on one side and plain
on the other.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>IRESSA comes in blister packs of 30 tablets. The blister foil may be
perforated or non-perforated.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>AstraZeneca AB</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>SE&#8209;151 85</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>S&ouml;dert&auml;lje</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Sweden</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal><span lang=SV style='color:black'>AstraZeneca AB</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>G&auml;rtunav&auml;gen</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>SE&#8209;151 85
S&ouml;dert&auml;lje</span></p>

<p class=MsoNormal><span lang=SV style='color:black'>Sweden</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='background:silver'>AstraZeneca UK Limited</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='background:silver'>Macclesfield</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='background:silver'>Cheshire SK10 2NA</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB style='background:silver'>United Kingdom</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AstraZeneca S.A./N.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +32 2 370 48 11</span></p>
  <p class=MsoNormal style='margin-right:1.7pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=PT>UAB AstraZeneca<b> </b>Lietuva</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +370 5 2660550</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt;text-autospace:
  none'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#1040;&#1089;&#1090;&#1088;&#1072;&#1047;&#1077;&#1085;&#1077;&#1082;&#1072;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  +359 (2) 44 55 000</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt;text-autospace:
  none'><span lang=FR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=FR>AstraZeneca S.A./N.V.</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l/Tel: +32 2 370 48 11</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt;text-autospace:
  none'><span lang=FR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:50.75pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AstraZeneca Czech Republic s.r.o.</span></p>
  <p class=MsoNormal><span lang=NO-BOK>Tel: </span><span lang=CS
  style='color:black'>+420 222 807 111</span></p>
  <p class=MsoNormal><span lang=NO-BOK>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=FR>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=NO-BOK>AstraZeneca Kft.</span></p>
  <p class=MsoNormal><span lang=PT>Tel.: +36 1 883 6500</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><s><span lang=PT><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Danmark</span></b></p>
  <p class=MsoNormal><span lang=DE>AstraZeneca A/S</span></p>
  <p class=MsoNormal><span lang=DE>Tlf: +45 43 66 64 62</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Malta</span></b></p>
  <p class=MsoNormal><span lang=PT>Associated Drug Co. Ltd</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=DE>Tel:
  +356 2277 8000</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><s><span lang=DE><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE>AstraZeneca GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +49 41 03 7080</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=DE>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE>AstraZeneca BV</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +31 79 363 2222</span></p>
  <p class=MsoNormal><s><span lang=DE><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Eesti</span></b></p>
  <p class=MsoNormal><span lang=FI>AstraZeneca</span></p>
  <p class=MsoNormal><span lang=FI>Tel: +372 6549 600</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=FI>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK>Norge</span></b></p>
  <p class=MsoNormal><span lang=NO-BOK>AstraZeneca AS</span></p>
  <p class=MsoNormal><span lang=NO-BOK>Tlf: +47 21 00 64 00</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><s><span
  lang=NO-BOK><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EL>AstraZeneca A.E.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +30 2 106871500</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=EL>AstraZeneca &Ouml;sterreich GmbH</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +43 1 711 31 0</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><s><span lang=DE><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>AstraZeneca Farmac&eacute;utica Spain, S.A.</span></p>
  <p class=MsoNormal><span lang=ES>Tel: +34 91 301 91 00</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=PL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>AstraZeneca Pharma Poland Sp. z o.o.</span></p>
  <p class=MsoNormal><span lang=PL>Tel.: +48 22 245 73 00</span></p>
  <p class=MsoNormal><s><span lang=PL><span style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>France</span></b></p>
  <p class=MsoNormal><span lang=FR>AstraZeneca</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l: +33 1 41 29 40 00</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>AstraZeneca Produtos Farmac&ecirc;uticos, Lda.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 21 434 61 00</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><s><span lang=PT><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><b><span style='font-size:11.0pt'>Hrvatska</span></b></p>
  <p class=A-TableText style='margin:0in'><span lang=HR>AstraZeneca d.o.o.</span></p>
  <p class=MsoNormal><span lang=HR>Tel: +385 1 4628 000</span></p>
  <p class=MsoNormal><span lang=HR>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=FR>AstraZeneca Pharma SRL</span></p>
  <p class=MsoNormal><span lang=PL>Tel: +40 21 317 60 41</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AstraZeneca Pharmaceuticals (Ireland) Ltd</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 1609 7100</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AstraZeneca UK Limited</span></p>
  <p class=MsoNormal>Tel: +386 1 51 35 600</p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><s><span lang=IT><span
   style='text-decoration:none'>&nbsp;</span></span></s></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>&Iacute;sland</span></b></p>
  <p class=MsoNormal><span lang=IT>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=NL>S</span><span lang=CS>&iacute;</span><span
  lang=NL>mi: +354 535 7000</span></p>
  <p class=MsoNormal><span lang=NL>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Slovensk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=NL>AstraZeneca AB, o.z.</span></p>
  <p class=MsoNormal><span lang=NL>Tel: +421 2 5737 7777 </span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><b><s><span
  lang=IT style='color:green'><span style='text-decoration:none'>&nbsp;</span></span></s></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>AstraZeneca S.p.A.</span></p>
  <p class=MsoNormal><span lang=IT>Tel: </span>+39 02 9801 1</p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FI>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=FI>AstraZeneca Oy</span></p>
  <p class=MsoNormal><span lang=FI>Puh/Tel: +358 10 23 010</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=EL>&#913;&#955;&#941;&#954;&#964;&#969;&#961;
  &#934;&#945;&#961;&micro;&#945;&#954;&#949;&#965;&#964;&#953;&#954;&#942;
  &#923;&#964;&#948;</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;: +357 22490305</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><b>&nbsp;</b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV>Sverige</span></b></p>
  <p class=MsoNormal><span lang=SV>AstraZeneca AB</span></p>
  <p class=MsoNormal><span lang=SV>Tel: +46 8 553 26&nbsp;000</span></p>
  <p class=MsoNormal><span lang=EL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Latvija</b></p>
  <p class=MsoNormal>SIA AstraZeneca Latvija</p>
  <p class=MsoNormal><span lang=PT>Tel: +</span><span lang=LV style='color:
  black'>371 67377100</span></p>
  <p class=A-TableText style='margin:0in;line-height:13.0pt'><span lang=PT>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>AstraZeneca UK Ltd</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 1582 836&nbsp;836</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB style='color:blue'><a
href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
